23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Ventyx Biosciences, Inc. › 2025-2026

Ventyx Biosciences, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Ventyx Biosciences, Inc.’s Form 8-K, filed March 3, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 3Reported items
  • 116Asset managers, any item
  • 314Fund votes
  • March 3, 2026Meeting date

Results at a glance

Meeting of March 3, 2026: 2 items on Ventyx Biosciences, Inc.’s Form 8-K, filed March 3, 2026: 2 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Ventyx Biosciences, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Ventyx Biosciences, Inc.

These tallies are Ventyx Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed March 3, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Ventyx Biosciences, Inc. — official shareholder meeting results, meeting held March 3, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
1. To adopt the Merger Agreement 44,176,7851,572,59261,369 ---- 97%Passed (calculated)—
2. To approve, on a non-binding, advisory basis, the compensation that will or may become payable by the Company to the Company's named executive officers in connection with the Merger 43,789,6931,838,898182,155 ---- 96%Passed (calculated)—

Source: Ventyx Biosciences, Inc., Form 8-K, filed with the SEC on March 3, 2026 — read the filing on EDGAR.

How asset managers voted at the Ventyx Biosciences, Inc. 2025-2026 meeting

116 asset managers disclosed a vote on at least one Ventyx Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Ventyx Biosciences, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

To adopt the Merger Agreement

Calculated outcomeCORPORATE GOVERNANCEPassed (calculated)

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 44,176,785AGAINST: 1,572,592
Details: description as filed, official tally, votes by 29 asset managers

Description as filed by funds: To adopt the Agreement and Plan of Merger (as it may be amended from time to time), dated as of January 7, 2026, by and among Eli Lilly and Company, RYLS Merger Corporation ("merger sub"), and Ventyx Biosciences, Inc. (the "merger agreement");

Ventyx Biosciences, Inc.’s own tally for this item (“1. To adopt the Merger Agreement”): 44,176,785 for, 1,572,592 against, per its Form 8-K filed March 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 9,776,756 for.

FOR
FOR: 9,776,756
Largest asset managers voting on “To adopt the Agreement and Plan of Merger (as it may be amended from time to time), dated as of January 7, 202” at Ventyx Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,909,9120 00For
BlackRock2,814,3020 00For
Investment Managers Series Trust II1,047,0850 00For
Fidelity694,2230 00For
Delaware/Macquarie430,0000 00For
Charles Schwab381,7580 00For
ARBITRAGE FUNDS300,5760 00For
State Street286,7890 00For
Dimensional246,6190 00For
BRIDGEWAY FUNDS INC129,9000 00For
ALTSHARES TRUST127,6490 00For
American Century107,1300 00For
Goldman Sachs71,7100 00For
ProShares40,9420 00For
PIMCO35,3000 00For
ETFis Series Trust I34,3990 00For
GDL FUND32,3330 00For
Morningstar Funds Trust29,8660 00For
Direxion Shares ETF Trust14,9470 00For
Equitable12,1470 00For
Victory Capital7,2860 00For
Jackson National6,0170 00For
SA FUNDS INVESTMENT TRUST4,2640 00For
Blackstone Alternative Investment Funds4,2000 00For
Invesco3,8910 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

To adjourn the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if…

No official matchCORPORATE GOVERNANCE

97% of fund votes cast · no official result

FOR
Details: description as filed, votes by 29 asset managers

Description as filed by funds: TO ADJOURN THE SPECIAL MEETING TO A LATER DATE OR DATES, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE INSUFFICIENT VOTES TO ADOPT THE MERGER AGREEMENT AT THE TIME OF THE SPECIAL MEETING.

The 29 asset managers below reported 9,489,967 for, 286,789 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 9,489,967AGAINST: 286,789
Largest asset managers voting on “TO ADJOURN THE SPECIAL MEETING TO A LATER DATE OR DATES, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PR” at Ventyx Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,909,9120 00For
BlackRock2,814,3020 00For
Investment Managers Series Trust II1,047,0850 00For
Fidelity694,2230 00For
Delaware/Macquarie430,0000 00For
Charles Schwab381,7580 00For
ARBITRAGE FUNDS300,5760 00For
State Street0286,789 00Against
Dimensional246,6190 00For
BRIDGEWAY FUNDS INC129,9000 00For
ALTSHARES TRUST127,6490 00For
American Century107,1300 00For
Goldman Sachs71,7100 00For
ProShares40,9420 00For
PIMCO35,3000 00For
ETFis Series Trust I34,3990 00For
GDL FUND32,3330 00For
Morningstar Funds Trust29,8660 00For
Direxion Shares ETF Trust14,9470 00For
Equitable12,1470 00For
Victory Capital7,2860 00For
Jackson National6,0170 00For
SA FUNDS INVESTMENT TRUST4,2640 00For
Blackstone Alternative Investment Funds4,2000 00For
Invesco3,8910 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

To approve, on a non-binding, advisory basis, the compensation that will or may become payable by the Company to the…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 43,789,693AGAINST: 1,838,898
Details: description as filed, official tally, votes by 116 asset managers

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation that will or may become payable by Ventyx Biosciences, Inc. to its named executive officers in connection with the merger of merger sub with and into Ventyx Biosciences, Inc.; and

Ventyx Biosciences, Inc.’s own tally for this item (“2. To approve, on a non-binding, advisory basis, the compensation that will or may become payable by the Company to the Company's named executive officers in connection with the Merger”): 43,789,693 for, 1,838,898 against, per its Form 8-K filed March 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 29 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation that will or may become payable by Ventyx Biosc” at Ventyx Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,909,9120 00For
BlackRock2,814,3020 00For
Investment Managers Series Trust II1,047,0850 00For
Fidelity694,2230 00For
Delaware/Macquarie430,0000 00For
Charles Schwab381,7580 00For
ARBITRAGE FUNDS300,5760 00For
State Street286,7890 00For
Dimensional246,6190 00For
BRIDGEWAY FUNDS INC129,9000 00For
ALTSHARES TRUST127,6490 00For
American Century0107,130 00Against
Goldman Sachs71,7100 00For
ProShares40,9420 00For
PIMCO35,3000 00For
ETFis Series Trust I34,3990 00For
GDL FUND32,3330 00For
Morningstar Funds Trust29,8660 00For
Direxion Shares ETF Trust14,9470 00For
Equitable12,1470 00For
Victory Capital7,2860 00For
Jackson National6,0170 00For
SA FUNDS INVESTMENT TRUST4,2640 00For
Blackstone Alternative Investment Funds4,2000 00For
Invesco3,8910 00For

Fund voting reports, all 29 managers: 9,669,302 for, 107,454 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 96 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation that will or may become payable by Ventyx Biosc” at Ventyx Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Affinity Asset Advisors, LLC3,781,6800 00For
GLAZER CAPITAL, LLC2,745,1750 00For
BAKER BROS. ADVISORS LP2,349,2800 00For
BlackRock1,378,1060 00For
TIG Advisors, LLC1,027,1130 00For
683 Capital Management, LLC926,8500 00For
GEODE CAPITAL MANAGEMENT, LLC728,7980 00For
BALYASNY ASSET MANAGEMENT L.P.723,2260 00For
AQR699,0230 00For
Artia Global Partners LP695,9820 00For
State Street588,3800 00For
Connor, Clark & Lunn Investment Management Ltd.584,1270 00For
Woodline Partners LP562,5000 00For
Renaissance504,0360 00For
WATER ISLAND CAPITAL LLC461,1590 00For
Vanguard446,2100 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST430,0000 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.427,1260 00For
Magnetar Financial LLC416,6600 00For
ADAR1 Capital Management, LLC412,8730 00For
Charles Schwab382,5310 00For
PACIFIC INVESTMENT MANAGEMENT CO LLC251,9000 00For
Two Sigma235,0840 00For
Twin Securities, Inc.233,3070 00For
HARVEST MANAGEMENT LLC175,1870 00For

Institutional-manager reports, all 96 managers: 22,804,967 for, 135,495 against, 35,299 abstained, 1,375 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Largest Ventyx Biosciences, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 71,358,638 shares outstanding at the time of that meeting.

Fund voting reports: top Ventyx Biosciences, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation that will or may become payable…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 4.08%
2BlackRock 3.94%
3Investment Managers Series Trust II 1.47%
4Fidelity 0.97%
5Delaware/Macquarie 0.60%
6Charles Schwab 0.53%
7ARBITRAGE FUNDS 0.42%
8State Street 0.40%
9Dimensional 0.35%
10BRIDGEWAY FUNDS INC 0.18%
Institutional-manager reports: top Ventyx Biosciences, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation that will or may become payable…”, 2025-2026
#Asset manager % of shares outstanding
1Affinity Asset Advisors, LLC 5.30%
2GLAZER CAPITAL, LLC 3.85%
3BAKER BROS. ADVISORS LP 3.29%
4BlackRock 1.93%
5TIG Advisors, LLC 1.44%
6683 Capital Management, LLC 1.30%
7GEODE CAPITAL MANAGEMENT, LLC 1.02%
8BALYASNY ASSET MANAGEMENT L.P. 1.01%
9AQR 0.98%
10Artia Global Partners LP 0.98%

Reported Ventyx Biosciences, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Ventyx Biosciences, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Bank of America Corporation4,616,536 6.47%Proxy statement (DEF 14A), table as of April 10, 2025
Entities affiliated with Point72 Asset Management, L.P.4,400,325 6.17%Proxy statement (DEF 14A), table as of April 10, 2025
Raju Mohan4,387,682 6.15%Schedule 13D, filed January 9, 2026
Morgan Stanley4,292,951 6.02%Form 13F, quarter ended March 31, 2026
Entities affiliated with Citadel Advisors LLC4,279,553 6.00%Proxy statement (DEF 14A), table as of April 10, 2025
Somasundaram Subramaniam, M.B.A.4,122,975 5.78%Proxy statement (DEF 14A), table as of April 10, 2025
Entities affiliated with New Science Ventures4,032,213 5.65%Proxy statement (DEF 14A), table as of April 10, 2025
Vanguard Group3,943,566 5.53%Form 13F, quarter ended March 31, 2026
BlackRock, Inc.3,814,531 5.35%Proxy statement (DEF 14A), table as of April 10, 2025
Sheila Gujrathi, M.D.1,221,072 1.71%Proxy statement (DEF 14A), table as of April 10, 2025

Percentages above are of 71,358,638 shares outstanding, as reported by Ventyx Biosciences, Inc. on its Form 10-Q dated November 3, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Ventyx Biosciences, Inc.'s shareholder meeting held March 3, 2026, in the 2025-2026 proxy season, 116 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 314 separate fund positions. Their filings are grouped here into 3 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation that will or may become payable… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Ventyx Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on March 3, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Ventyx Biosciences, Inc.’s 10-Q dated November 3, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Ventyx Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Ventyx Biosciences, Inc. 2026 Special Meeting: Vote Results”, https://proxyvotesnow.com/company/ventyx-biosciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.